Anton G T Terwisscha van Scheltinga Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

8/2017

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anton G T Terwisscha van Scheltinga Research Topics

Disease

21	Neoplasms (Cancer) 01/2020 - 11/2011
3	Breast Neoplasms (Breast Cancer) 11/2017 - 01/2017
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 01/2018
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 11/2012
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 12/2015
1	Colonic Neoplasms (Colon Cancer) 01/2020
1	Rectal Neoplasms (Rectal Cancer) 01/2020
1	Carcinoma (Carcinomatosis) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2017
1	Mesothelioma 01/2017
1	Prostatic Neoplasms (Prostate Cancer) 05/2016
1	Leukemia 01/2016
1	Bites and Stings (Sting) 01/2016
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2016
1	Triple Negative Breast Neoplasms 09/2014
1	Atherosclerotic Plaque (Atheroma) 06/2013
1	Esophageal Neoplasms (Esophageal Cancer) 06/2013

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 03/2019 - 06/2013
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2017 - 11/2011
4	ErbB Receptors (EGF Receptor)IBA 10/2017 - 10/2016
4	Bevacizumab (Avastin)FDA Link 01/2017 - 11/2011
3	Proteins (Proteins, Gene)FDA Link 11/2017 - 11/2012
3	Zirconium-89IBA 11/2017 - 07/2014
3	Monoclonal AntibodiesIBA 10/2017 - 10/2016
3	Immunoconjugates (Immunoconjugate)IBA 01/2017 - 12/2015
3	89Zr-bevacizumabIBA 06/2013 - 11/2012
2	human ERBB2 proteinIBA 11/2017 - 11/2011
2	Tyrosine Kinase InhibitorsIBA 11/2017 - 08/2017
2	lumretuzumabIBA 10/2017 - 07/2014
2	monomethyl auristatin EIBA 01/2017 - 05/2016
2	MesothelinIBA 01/2017 - 12/2015
2	Fluorescent Dyes (Fluorescent Probes)IBA 01/2017 - 01/2016
2	IRDye 800CWIBA 01/2016 - 12/2015
2	Biomarkers (Surrogate Marker)IBA 07/2014 - 11/2012
1	Peptides (Polypeptides)IBA 01/2020
1	IntegrinsIBA 01/2020
1	Lapatinib (GW572016)FDA Link 11/2017
1	LigandsIBA 08/2017
1	onartuzumabIBA 08/2017
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2017
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2017
1	89Zr-MSB0010853IBA 01/2017
1	Epithelial Cell Adhesion MoleculeIBA 01/2016
1	Differentiation AntigensIBA 12/2015
1	AntigensIBA 12/2015
1	Insulin-Like PeptidesIBA 09/2014
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 09/2014
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2014
1	Dihydrotachysterol (AT 10)IBA 04/2014
1	PRS-110IBA 04/2014
1	zirconium-89-trastuzumabIBA 06/2013
1	MTOR InhibitorsIBA 11/2012
1	Everolimus FDA Link 11/2012
1	AntibodiesIBA 11/2011
1	Trastuzumab (Herceptin)FDA Link 11/2011

Therapy/Procedure

2	Therapeutics 01/2017 - 11/2012
1	Neoadjuvant Therapy 01/2020
1	Castration 05/2016
1	Intravenous Administration 01/2016
1	Aftercare (After-Treatment) 06/2013